FDA Inspection 1049402 — BioAgilytix
The FDA completed an inspection of BioAgilytix on March 2, 2018 in Hamburg. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- March 2, 2018
- Fiscal Year
- 2018
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Hamburg (Germany)
Additional Details
Bioanalytical BA/BE